• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

KRAS Gene Record

  • Summary
  • Interactions
  • Claims
  • KRAS 3845 Clinically ActionableDrug Resistance

    Alternate Names:

    3845
    KRAS PROTO-ONCOGENE, GTPASE
    KRAS
    C-K-RAS
    CFC2
    K-RAS2A
    K-RAS2B
    K-RAS4A
    K-RAS4B
    K-Ras
    KI-RAS
    KRAS1
    KRAS2
    NS
    NS3
    RALD
    RASK2
    c-Ki-ras2
    190070
    6407
    ENSG00000133703
    OTTHUMG00000171193
    PA30196
    3485
    P01116
    30
    GTPase KRas
    T48598
    'C-K-RAS
    K-Ras 2
    OES
    c-Ki-ras

    Gene Info:

    CancerCommons Reported Gene Name KRAS-RAS
    Target Class Miscellaneous
    Target Subclass Miscellaneous
    Target Subclass Hras
    Gene Biotype PROTEIN_CODING
    (13 More Sources)

    Gene Categories: Category Details

    DRUG RESISTANCE
    CLINICALLY ACTIONABLE

    Publications:

    Roper et al., 2014, Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer., Cancer Lett.
    Vansteenkiste et al., 2015, Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study., J Thorac Oncol
    Hong et al., 2016, Targeting the PI3K signaling pathway in KRAS mutant colon cancer., Cancer Med
    Park et al., 2012, NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations., Int. J. Oncol.
    Gerdes et al., 2013, GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab., Clin. Cancer Res.
    Bertino et al., 2016, A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer., Mol. Cancer Ther.
    Hatzivassiliou et al., 2013, Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers., Nature
    Hoeflich et al., 2012, Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition., Cancer Res.
    Papadimitrakopoulou et al., 2016, The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer., J. Clin. Oncol.
    Hu et al., 2015, Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models., Mol. Cancer Ther.
    Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell
    Yap et al., 2011, First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors., J. Clin. Oncol.
    Riquelme et al., 2016, Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations., Cancer Res.
    Horn et al., 2016, High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells., Cancer Res.
    Eberlein et al., 2015, Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models., Cancer Res.
    Pao et al., 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib., PLoS Med.
    Manchado et al., 2016, A combinatorial strategy for treating KRAS-mutant lung cancer., Nature
    Ludovini V et al., 2011, Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer., J Thorac Oncol
    Marchetti et al., 2009, Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones., Neoplasia
    Fiala et al., The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer., Cancer Genet
    Kim et al., 2017, Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review., Oncotarget
    Martinelli et al., 2013, Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells., Int. J. Cancer
    Paz-Ares et al., 2015, Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens., J Thorac Oncol
    Dingemans et al., 2013, A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation., Clin. Cancer Res.
    Wilson et al., 2016, Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma., Clin. Cancer Res.
    Lim et al., 2014, A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma., Clin. Cancer Res.
    Falchook et al., 2015, Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors., Invest New Drugs
    Gandara et al., 2017, A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer., J Thorac Oncol
    Sun et al., 2014, Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3., Cell Rep
    Jing et al., 2012, Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212., Mol. Cancer Ther.
    Infante et al., 2014, A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas., Eur. J. Cancer
    Ball et al., 2015, Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer., Oncol. Rep.
    Beadnell et al., 2016, The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer., Mol. Cancer Ther.
    Gannon et al., 2016, Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy., Mol. Cancer Res.
    Yamaguchi et al., 2016, A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers., Oncotarget
    Brammeld et al., 2017, Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations., Genome Res.
    Lin et al., 2015, The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies., Nat. Genet.
    Infante et al., 2012, Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial., Lancet Oncol.
    Dhawan et al., 2016, Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling., Nature
    Peng et al., 2015, Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers., Cancer Cell
    Oddo et al., 2016, Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer., Cancer Res.
    Ziemke et al., 2016, Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6., Clin. Cancer Res.
    Russo et al., 2016, Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer., Cancer Discov
    Li et al., 2013, The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere., J Transl Med
    Yoon et al., 2009, Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells., Mol. Cancer Ther.
    De Roock et al., 2010, Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab., JAMA
    Janssen et al., 1987, RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes., Proc. Natl. Acad. Sci. U.S.A.
    Lee et al., 2011, Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations., J. Natl. Cancer Inst.
    Neumann et al., 2009, Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer., Pathol. Res. Pract.
    Amado et al., 2008, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer., J. Clin. Oncol.
    Tyner et al., 2009, High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients., Blood
    Peeters et al., 2013, Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab., J. Clin. Oncol.
    Haldar et al., 2011, Epidermal growth factor receptor blockers for the treatment of ovarian cancer., Cochrane Database Syst Rev
    Rowland et al., 2016, Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours., Eur. J. Cancer
    Nakayama et al., 2008, KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer., Br. J. Cancer
    Ho et al., 2013, Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer., N. Engl. J. Med.
    Tejpar et al., 2012, Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab., J. Clin. Oncol.
    Bokemeyer et al., 2009, Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer., J. Clin. Oncol.
    Lièvre et al., 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer., Cancer Res.
    MacConaill et al., 2014, Prospective enterprise-level molecular genotyping of a cohort of cancer patients., J Mol Diagn
    Bokemeyer et al., 2011, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study., Ann. Oncol.
    Schubbert et al., 2007, Hyperactive Ras in developmental disorders and cancer., Nat. Rev. Cancer
    Kloos et al., 2009, Phase II trial of sorafenib in metastatic thyroid cancer., J. Clin. Oncol.
    Schirripa et al., 2015, Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer., Ann. Oncol.
    Peeters et al., 2010, Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer., J. Clin. Oncol.
    Riely et al., 2008, Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma., Clin. Cancer Res.
    Bacher et al., 2006, Implications of NRAS mutations in AML: a study of 2502 patients., Blood
    Hoftijzer et al., 2009, Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma., Eur. J. Endocrinol.
    Migliardi et al., 2012, Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas., Clin. Cancer Res.
    Rothenberg et al., 2005, Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma., J. Clin. Oncol.
    Osumi et al., 2015, Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival., Mol Clin Oncol
    Sano et al., 2012, RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group., Int. J. Hematol.
    Kumar et al., 2014, KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model., Gastrointest Cancer Res
    Douillard et al., 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study., J. Clin. Oncol.
    Brose et al., 2002, BRAF and RAS mutations in human lung cancer and melanoma., Cancer Res.
    Vogelstein et al., 1990, RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study., Genes Chromosomes Cancer
    Janakiraman et al., 2010, Genomic and biological characterization of exon 4 KRAS mutations in human cancer., Cancer Res.
    Parseghian et al., 2017, Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer., Clin. Cancer Res.
    Venook et al., 2017, Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial., JAMA
    Ramos et al., 2008, Understanding the predictive role of K-ras for epidermal growth factor receptor-targeted therapies in colorectal cancer., Clin Colorectal Cancer
    Hechtman et al., 2015, AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants., Mol. Cancer Res.
    Ciardiello et al., 2016, Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX., Ann. Oncol.
    Osumi et al., 2013, Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report., BMC Res Notes
    Van Cutsem et al., 2015, Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer., J. Clin. Oncol.
    Napolitano et al., 2015, Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab., Clin. Cancer Res.
    Lièvre et al., 2008, KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab., J. Clin. Oncol.
    Pirazzoli et al., 2016, Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma., Clin. Cancer Res.
    Deming et al., 2016, A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer., Invest New Drugs
    Morgen EK et al., 2017, Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis., Pharmacogenomics J
    Allegra CJ et al., 2016, Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015., J Clin Oncol
    Sclafani F et al., 2015, Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial., Ann Oncol
    Ying HQ et al., 2014, The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis., Onco Targets Ther
    Saridaki Z et al., 2014, A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy., Clin Cancer Res
    Sha D et al., 2014, Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial)., Clin Cancer Res
    Sebio A et al., 2013, The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients., Pharmacogenet Genomics
    Chen J et al., 2013, Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis., Cancer Chemother Pharmacol
    Bando H et al., 2012, Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan., Jpn J Clin Oncol
    Gajate P et al., 2012, Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab., Clin Colorectal Cancer
    Kaczirek et al., 2015, FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study., Clin Colorectal Cancer
    Loupakis et al., 2009, KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer., Br. J. Cancer
    Misale et al., 2012, Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer., Nature
    Benson et al., 2017, Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology., J Natl Compr Canc Netw
    Bertotti et al., 2011, A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer., Cancer Discov
    Dunn et al., 2011, Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab., Oncogene
    Sartore-Bianchi et al., 2009, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies., Cancer Res.
    Souglakos J et al., 2009, Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer., Br J Cancer
    De Roock et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol.
    Karapetis et al., 2008, K-ras mutations and benefit from cetuximab in advanced colorectal cancer., N. Engl. J. Med.
    Sato N et al., 2012, Cetuximab inhibits the growth of mucinous ovarian carcinoma tumor cells lacking KRAS gene mutations., Oncol Rep
    Valtorta E et al., 2013, KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy., Int J Cancer
    Ahronian et al., 2015, Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations., Cancer Discov
    French D et al., 2011, KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing., Clin Chim Acta
    Sartore-Bianchi et al., 2016, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial., Lancet Oncol.
    Lou et al., 2017, Therapeutic Response of Metastatic Colorectal Cancer Harboring a KRAS Missense Mutation After Combination Chemotherapy With the EGFR Inhibitor Panitumumab., J Natl Compr Canc Netw
    Leone et al., 2016, Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)., Cancer
    Poulin-Costello et al., 2013, An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer., Target Oncol
    Van Cutsem et al., 2014, Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer., Clin. Cancer Res.
    Peeters et al., 2015, Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer., Clin. Cancer Res.
    Herrero et al., 2015, Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes., Cancer Cell
    Nakanishi et al., 2015, ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor., Mol. Cancer Ther.
    Takekuma et al., 2016, A long-term surviving patient with recurrent low-grade serous ovarian carcinoma treated with the MEK1/2 inhibitor, selumetinib., Gynecol Oncol Res Pract
    Whittaker et al., 2015, Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors., Mol. Cancer Ther.
    Jänne et al., 2015, Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer., Br. J. Cancer
    Qian et al., 2014, Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets., Genes Chromosomes Cancer
    Jänne et al., 2013, Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study., Lancet Oncol.
    Jänne et al., 2017, Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial., JAMA
    McNew et al., 2016, MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling., Mol. Cancer Res.
    Qu et al., 2014, Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models., J. Exp. Clin. Cancer Res.
    Holt et al., 2012, Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055)., Cancer Res.
    Engelman et al., 2008, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers., Nat. Med.
    Hofmann et al., 2012, K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo., PLoS ONE
    García-García et al., 2015, MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer., Clin. Cancer Res.
    Depreeuw et al., 2015, Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies., Gynecol. Oncol.
    Kim et al., 2016, Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer., Mol. Cancer Res.
    Hochster et al., 2015, Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer., Cancer Chemother. Pharmacol.
    Ebi et al., 2011, Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers., J. Clin. Invest.
    Lamba et al., 2014, RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells., Cell Rep
    Ross et al., 2017, Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS., Sci Transl Med
    Yu et al., 2014, Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway., Mol. Cancer Ther.
    Mallon et al., 2010, Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor., Mol. Cancer Ther.
    Brugger et al., 2011, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer., J. Clin. Oncol.
    Kim et al., 2011, Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy., Mol. Cancer Ther.
    Zhu et al., 2008, Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21., J. Clin. Oncol.
    Eberhard et al., 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib., J. Clin. Oncol.
    Chung et al., 2014, A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma., Ann. Oncol.
    Kang et al., 2016, ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models., Lung Cancer
    Richer et al., 2017, WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer., Cancer Res.
    Wilhelm et al., 2011, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity., Int. J. Cancer
    Loaiza-Bonilla et al., 2016, KDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal Cancer., Cureus
    Saha et al., 2016, Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma., Cancer Discov
    Maitra et al., 2014, Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan., Oncotarget
    Mahalingam et al., 2015, The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer., BMC Cancer
    Danilov et al., 2016, Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2., Mol. Cancer Ther.
    Ahmed et al., 2013, Epigenetic and genetic features of 24 colon cancer cell lines., Oncogenesis
    Smakman et al., 2006, KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand., Cancer Res.
    Mallon et al., 2011, Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor., Clin. Cancer Res.
    Canon et al., 2015, The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents., Mol. Cancer Ther.
    Ortiz-Cuaran et al., 2016, Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors., Clin. Cancer Res.
    Kumar et al., 2012, The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer., Cell
    Schmitt et al., 2017, ATM Deficiency Is Associated with Sensitivity to PARP1- and ATR Inhibitors in Lung Adenocarcinoma., Cancer Res.
    Patnaik et al., 2016, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors., Cancer Discov
    Glover et al., 1992, Gastroenteritis outbreak at an industrial camp--British Columbia., Can. Commun. Dis. Rep.
    Sherr et al., 2016, Targeting CDK4 and CDK6: From Discovery to Therapy., Cancer Discov
    Montero et al., 2016, A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors., Clin. Cancer Res.
    Modest et al., 2013, KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer., J. Cancer Res. Clin. Oncol.
    Soares et al., 2015, Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2., Mol. Cancer Ther.
    Wallin et al., 2011, GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway., Mol. Cancer Ther.
    Liu et al., 2013, BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models., Mol. Cancer Ther.
    Fernandes MS et al., 2016 Oct 18, Specific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancers., Oncotarget
    Fritsch et al., 2014, Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials., Mol. Cancer Ther.
    Anderson et al., 2016, PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation., Sci Transl Med
    Tabernero et al., 2015, Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study., Lancet Oncol.
    Lee et al., 2016, Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models., Oncotarget
    Hamidi et al., 2014, KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition., Br. J. Cancer
    Bendell et al., 2017, A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor., Br. J. Cancer
    Raja et al., 2015, Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer., Mol. Cancer Ther.
    Monk BJ et al., 2020, MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum., J Clin Oncol
    Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.
    Scholl et al., 2009, Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells., Cell
    Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
    Myers et al., 2016, Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study., Gynecol. Oncol.
    Lin et al., 2012, KRAS mutation is a predictor of oxaliplatin sensitivity in colon cancer cells., PLoS ONE
    Raats et al., 2011, Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737., Cell Oncol (Dordr)
    Elez et al., 2016, Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer., Br. J. Cancer
    Momcilovic et al., 2015, Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers., Cancer Res.
    Kavuri et al., 2015, HER2 activating mutations are targets for colorectal cancer treatment., Cancer Discov
    Shoji et al., 2012, Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas., PLoS ONE
    Di Nicolantonio et al., 2010, Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus., J. Clin. Invest.
    Mohseni et al., 2010, PIK3CA and KRAS mutations predict for response to everolimus therapy: now that's RAD001., J. Clin. Invest.
    Gálvez-Peralta et al., 2014, Context-dependent antagonism between Akt inhibitors and topoisomerase poisons., Mol. Pharmacol.
    Dumble et al., 2014, Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor., PLoS ONE
    Egile et al., 2015, The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer., Mol. Cancer Ther.
    Van Laethem et al., 2017, Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer., Target Oncol
    O'Neil et al., 2015, A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer., Ann. Oncol.
    Osborne et al., 2016, Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)., J. Med. Chem.
    Vena et al., 2015, The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)., Clin. Cancer Res.
    Juric et al., 2017, Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors., Cancer Discov
    Yap et al., 2012, AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity., Clin. Cancer Res.
    Hudson et al., 2016, Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers., Mol. Cancer Ther.
    Leijen et al., 2016, Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months., J. Clin. Oncol.
    Foster et al., 2015, The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models., Mol. Cancer Ther.
    Ratner et al., 2012, A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer., Oncogene
    Yeh et al., 2009, KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer., Mol. Cancer Ther.
    Kim et al., 2013, Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer., Int. J. Cancer
    Riely et al., 2011, A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations., J Thorac Oncol
    Laheru D et al., 2012, Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer., Invest New Drugs
    Yuan et al., 2011, PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity., Mol. Cancer Ther.
    Mortensen et al., 2015, CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization., Mol. Cancer Ther.
    Athuluri-Divakar et al., 2016, A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling., Cell
    Weisberg et al., 2015, Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies., Leukemia
    Mahoney et al., 2009, LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition., Br. J. Cancer
    Ambrogio et al., 2016, Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma., Nat. Med.
    Sherman et al., 2016, Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer., Cancer
    Bhagwat et al., 2011, Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin., Mol. Cancer Ther.
    Dong et al., 2017, Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma., Clin. Cancer Res.
    Chen et al., 2017, KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma., Cancer Immunol. Immunother.
    Dietlein et al., 2015, A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer., Cell
    Ferrarotto et al., 2016, Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Kashiyama et al., 2014, Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423., PLoS ONE
    Petrelli et al., 2013, KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials., Med. Oncol.
    Palm et al., 2015, The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1., Cell
    Perera et al., 2017, Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor., Mol. Cancer Ther.
    Yang et al., 2008, Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer., PLoS ONE
    Ma et al., 2013, K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin., Mol Med Rep
    Iglesias et al., 2013, Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy., Mol. Cancer Ther.
    Xie J et al., 2020, Metformin selectively inhibits metastatic colorectal cancer with the <i>KRAS</i> mutation by intracellular accumulation through silencing MATE1., Proc Natl Acad Sci U S A
    Song et al., 2015, Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer., Clin. Cancer Res.
    Zimmer et al., 2014, Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations., Clin. Cancer Res.
    Stewart et al., 2015, KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine., Cancer Res.
    Hunter et al., 2015, Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations., Mol. Cancer Res.
    Boasberg et al., 2011, Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer., Cancer Chemother. Pharmacol.
    Simmons et al., 2012, Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice., Cancer Chemother. Pharmacol.
    Lee et al., 2010, Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer., Oncol. Rep.
    Nam et al., 2011, Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer., Cancer Lett.
    Hollestelle et al., 2007, Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines., Mol. Cancer Res.
    Acquaviva et al., 2012, Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib., Mol. Cancer Ther.
    Davies et al., 2002, Mutations of the BRAF gene in human cancer., Nature
    Palma et al., 2014, Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary., Case Rep Oncol
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
    Lieu et al., 2015, Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts., Oncotarget
    Tanaka et al., 2011, The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations., Clin. Cancer Res.
  • AZD-4785   KRAS

    Interaction Score: 1.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung cancer
    Approval Status Preclinical - Pdx
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    28615361


    Sources:
    JAX-CKB TTD

  • PANITUMUMAB   KRAS

    Interaction Score: 1.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Variant Effect gain-of-function
    Pathway activation
    Clinical Status FDA-rejected

    PMIDs:
    20978259 3122217 21398618 19679400 18316791 19075190 23182985 21975775 26812186 19018267 23406027 22734028 19114683 16618717 25157968 21228335 17384584 19255327 26371285 20921462 18794081 16434492 19773371 22392911 16361624 26623049 22407852 24558511 20921465 12460918 2278970 28404754 26540314 23625191 24919569 19064407 26341920 28275037 19223544 27897268 26438111 26162609 25210463 25183481 24727325 23324806 23090619 23071293 22537608 23404247 26644315


    Sources:
    ClearityFoundationBiomarkers JAX-CKB DoCM CIViC PharmGKB OncoKB

  • CETUXIMAB   KRAS

    Interaction Score: 0.83

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Clinical Status late trials
    Pathway activation
    Variant Effect gain-of-function

    PMIDs:
    20978259 3122217 21398618 19679400 18316791 19075190 23182985 21975775 26812186 19018267 23406027 22734028 19114683 16618717 25157968 21228335 17384584 19255327 26371285 20921462 18794081 16434492 19773371 22392911 16361624 26623049 22407852 24558511 20921465 12460918 2278970 20570890 28179366 28280091 27458141 28632865 19064407 25714871 27002107 24304820 25605843 26715098 25838391 18202412 26341921 27312529 26666244 27897268 26438111 26162609 25210463 25183481 24727325 23324806 23090619 23071293 22537608 25666295 19603018 22722830 28275037 22586653 20956938 19223544 19603024 20619739 18946061 22246397 23404247 25673644 21575616


    Sources:
    ClearityFoundationBiomarkers JAX-CKB DoCM CIViC PharmGKB OncoKB

  • PELAREOREP   KRAS

    Interaction Score: 0.62

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy Reolysin + Gemcitabine
    Indication/Tumor Type pancreatic cancer
    Response Type sensitive

    PMIDs:
    24798549 26156229


    Sources:
    JAX-CKB CancerCommons

  • PD-0325901   KRAS

    Interaction Score: 0.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MLN0128 + PD-0325901
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    21325073 20570890 26582713 27556948 26037647 23934108 26267534 21516509 25673820 22684718 26272063


    Sources:
    JAX-CKB

  • XMT-1536   KRAS

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Preclinical - Pdx

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • CHEMBL217354   KRAS

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trametinib + TW-37
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    25665005


    Sources:
    JAX-CKB

  • RILOTUMUMAB   KRAS

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Rilotumumab + Panitumumab
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    24919569


    Sources:
    JAX-CKB

  • RALIMETINIB   KRAS

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ralimetinib + SCH772984
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • SAR-125844   KRAS

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type resistant

    PMIDs:
    25504634


    Sources:
    JAX-CKB

  • NECITUMUMAB   KRAS

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Necitumumab + FOLFOX
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive

    PMIDs:
    26766738


    Sources:
    JAX-CKB

  • IMGATUZUMAB   KRAS

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    23209031


    Sources:
    JAX-CKB

  • SELUMETINIB   KRAS

    Interaction Score: 0.41

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    combination therapy Osimertinib + Selumetinib
    Indication/Tumor Type thyroid cancer
    combination therapy Dasatinib + Selumetinib

    PMIDs:
    25870145 27222538 26438159 27312529 27556948 27231576 26351322 26125448 27480147 24935174 23200175 28492898 26725216 27655129 24939055 22271687 19029981 22952903 26272063 26232337 26676756 27422710 26666244 25322874 21985784 25199829 22392911


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC MyCancerGenomeClinicalTrial

  • CC-223   KRAS

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colon cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    24978597 25855786


    Sources:
    JAX-CKB

  • VOLASERTIB   KRAS

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26597303


    Sources:
    JAX-CKB

  • AZD-8835   KRAS

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    26839307


    Sources:
    JAX-CKB

  • RIDAFOROLIMUS   KRAS

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ridaforolimus + SCH772984
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • PHENFORMIN   KRAS

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MLN0128 + Phenformin
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive

    PMIDs:
    26574479


    Sources:
    JAX-CKB

  • TEPROTUMUMAB   KRAS

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21985784


    Sources:
    CIViC

  • BINIMETINIB   KRAS

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type decreased response
    Approval Status Preclinical - Cell culture

    PMIDs:
    27167191 27556948 25167228 28152546 26206338 27422710 32822286


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC OncoKB

  • AFATINIB   KRAS

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Afatinib + Cetuximab
    Indication/Tumor Type lung adenocarcinoma
    Response Type resistant

    PMIDs:
    25870145 27338794 26341921 24685132


    Sources:
    JAX-CKB CIViC

  • OSIMERTINIB   KRAS

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    25870145 27252416


    Sources:
    JAX-CKB

  • REFAMETINIB   KRAS

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Copanlisib + Refametinib
    Indication/Tumor Type biliary tract cancer
    Response Type sensitive

    PMIDs:
    26582713 27975152 25294897


    Sources:
    JAX-CKB

  • TRAMETINIB   KRAS

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pazopanib + Trametinib
    Indication/Tumor Type thyroid cancer
    combination therapy Dasatinib + Trametinib

    PMIDs:
    27876675 24685132 22169769 24915778 26324075 27222538 26582713 26882569 28179366 25665005 22805291 27556948 27659046 26343583 27338794 27312529 26369631 26644315


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC PharmGKB OncoKB

  • DOXIL   KRAS

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Temsirolimus + Doxil
    Indication/Tumor Type ovarian carcinoma
    Response Type sensitive

    PMIDs:
    21216929


    Sources:
    JAX-CKB

  • ULIXERTINIB   KRAS

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD8186 + BVD-523
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • SERABELISIB   KRAS

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type no benefit
    Approval Status Preclinical

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • DANUSERTIB   KRAS

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Danusertib + SCH772984
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • ENCORAFENIB   KRAS

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Encorafenib
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    27312529 25673644


    Sources:
    JAX-CKB CIViC

  • RG-7420   KRAS

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    23934108


    Sources:
    JAX-CKB

  • DEMCIZUMAB   KRAS

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Dasatinib + Demcizumab
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive

    PMIDs:
    26855149


    Sources:
    JAX-CKB

  • RAMUCIRUMAB   KRAS

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ramucirumab + FOLFIRI
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    25877855


    Sources:
    JAX-CKB PharmGKB

  • CHEMBL589258   KRAS

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    20371716


    Sources:
    JAX-CKB

  • DEL-22379   KRAS

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Cell culture
    Evidence Type Actionable
    Approval Status Preclinical

    PMIDs:
    26267534


    Sources:
    JAX-CKB

  • SALIRASIB   KRAS

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type no benefit
    Approval Status Phase II

    PMIDs:
    21847063 22547163


    Sources:
    JAX-CKB CIViC

  • PIMASERTIB   KRAS

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pimasertib + Gemcitabine
    Indication/Tumor Type pancreatic cancer
    Response Type sensitive

    PMIDs:
    23629727 26228206


    Sources:
    ClearityFoundationBiomarkers JAX-CKB

  • DEGUELIN   KRAS

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type stomach cancer
    Response Type predicted – sensitive
    Approval Status Preclinical

    PMIDs:
    24978597 20811676


    Sources:
    JAX-CKB

  • RO-4987655   KRAS

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type no benefit
    Approval Status Phase I

    PMIDs:
    26438159 24947927


    Sources:
    JAX-CKB

  • POZIOTINIB   KRAS

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type stomach cancer
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    21306821


    Sources:
    JAX-CKB

  • ABT 737   KRAS

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Oxaliplatin + ABT-737
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive

    PMIDs:
    21468686


    Sources:
    JAX-CKB

  • TAZEMETOSTAT   KRAS

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Selumetinib + Tazemetostat
    Indication/Tumor Type lung adenocarcinoma
    Response Type no benefit

    PMIDs:
    26676756


    Sources:
    JAX-CKB

  • AZD-8186   KRAS

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy AZD8186 + BVD-523
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • ABEMACICLIB   KRAS

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Evidence Type Actionable
    Approval Status Phase I

    PMIDs:
    27217383 1291017 26658964


    Sources:
    JAX-CKB CIViC

  • COBIMETINIB   KRAS

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Atezolizumab + Cobimetinib
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive

    PMIDs:
    23934108 22084396


    Sources:
    ClearityFoundationBiomarkers JAX-CKB OncoKB

  • MK-2206   KRAS

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy DZNep + MK2206
    Indication/Tumor Type pancreatic cancer
    Response Type sensitive

    PMIDs:
    27480147 25931518 26725216 22025163 26676756


    Sources:
    JAX-CKB

  • ERDAFITINIB   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung cancer
    Response Type resistant
    Approval Status Preclinical - Cell culture

    PMIDs:
    28341788


    Sources:
    JAX-CKB

  • PF-00477736   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy PF3644022 + PF-477736
    Indication/Tumor Type urinary bladder cancer
    Response Type predicted – sensitive

    PMIDs:
    26140595


    Sources:
    JAX-CKB

  • RIGOSERTIB   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type pancreatic cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    27104980 26091808


    Sources:
    JAX-CKB

  • NAVITOCLAX   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical
    Indication/Tumor Type non-small cell lung carcinoma
    combination therapy Trametinib + Navitoclax

    PMIDs:
    25665005 26725216 27659046


    Sources:
    JAX-CKB

  • A-443654   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colon cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    24569089 24978597


    Sources:
    JAX-CKB

  • TEMSIROLIMUS   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy SCH772984 + Temsirolimus
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    21216929 26725216 27016228


    Sources:
    ClearityFoundationBiomarkers JAX-CKB

  • DINACICLIB   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Dinaciclib + MK2206
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    27550941 25931518


    Sources:
    JAX-CKB

  • LY-3009120   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26343583


    Sources:
    JAX-CKB

  • CAPIVASERTIB   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type stomach cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    24088382 19755509


    Sources:
    JAX-CKB

  • CGM-097   KRAS

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy ABT-263 + Alpelisib + CGM097 + Trametinib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    27659046


    Sources:
    JAX-CKB

  • OSI-027   KRAS

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy OSI-027 + SCH772984
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    21673091 26725216


    Sources:
    JAX-CKB

  • LINSITINIB   KRAS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Linsitinib + SCH772984
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • AT-13148   KRAS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colon cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    22781553


    Sources:
    JAX-CKB

  • REGORAFENIB   KRAS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type breast cancer
    Approval Status Preclinical - Cell line xenograft
    Approval Status Preclinical - Cell culture

    PMIDs:
    21170960 23629727 27004155 25838391


    Sources:
    JAX-CKB MyCancerGenomeClinicalTrial PharmGKB OncoKB

  • IPATASERTIB   KRAS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • FIMEPINOSTAT   KRAS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type multiple myeloma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    19165201 20570890 22693356 19490892


    Sources:
    JAX-CKB

  • GEDATOLISIB   KRAS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    17314276 24042735 23012248 12068308 21325073 25688157 25673820


    Sources:
    JAX-CKB

  • DACTOLISIB   KRAS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    22392911 19029981 23629727 25673820 24939055 23475782 22662154 26272063 26232337 26206338


    Sources:
    JAX-CKB CIViC

  • NERATINIB   KRAS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Neratinib + Trastuzumab
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    26725216 26243863


    Sources:
    JAX-CKB

  • ERLOTINIB   KRAS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy ABT-263 + Alpelisib + Erlotinib + Trametinib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    21969500 21258250 19794967 23313110 15696205 21862683 18626007 16043828 27480147 27659046


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • AZD-8055   KRAS

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Cell culture
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    combination therapy AZD8055 + SCH772984

    PMIDs:
    26725216 22271687 24791855


    Sources:
    JAX-CKB

  • PA-799   KRAS

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    22159814 21558396


    Sources:
    JAX-CKB

  • TAK-733   KRAS

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type cholangiocarcinoma
    Response Type sensitive
    Approval Status Preclinical - Pdx

    PMIDs:
    26439693


    Sources:
    JAX-CKB

  • VISTUSERTIB   KRAS

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy SCH772984 + Vistusertib
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • SARACATINIB   KRAS

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type intrahepatic cholangiocarcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    26725216 27231123


    Sources:
    JAX-CKB

  • IRINOTECAN   KRAS

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Irinotecan + Selumetinib
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive

    PMIDs:
    20619739 24042735 16707468 21325073 23209031 25714871 24798549 26341920 25567130 25322874 21575616


    Sources:
    JAX-CKB CIViC

  • PANOBINOSTAT   KRAS

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Cell culture
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    combination therapy Panobinostat + SCH772984

    PMIDs:
    26725216 22693356 19490892


    Sources:
    JAX-CKB

  • ATEZOLIZUMAB   KRAS

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Atezolizumab + Cobimetinib
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive

    PMIDs:
    28525386


    Sources:
    JAX-CKB CIViC

  • CRIZOTINIB   KRAS

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type stomach cancer
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    25232318 27338794 26432108


    Sources:
    JAX-CKB

  • BERZOSERTIB   KRAS

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    28363999


    Sources:
    JAX-CKB

  • PEMETREXED   KRAS

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pemetrexed + GSK1120212
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive

    PMIDs:
    27876675


    Sources:
    JAX-CKB CIViC

  • BUPARLISIB   KRAS

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BKM120 + AG490
    Indication/Tumor Type stomach cancer
    Response Type sensitive

    PMIDs:
    24576621 26098748 26715098 22159814


    Sources:
    JAX-CKB

  • LIFIRAFENIB   KRAS

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • PICTILISIB   KRAS

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type myelodysplastic/myeloproliferative neoplasm
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    19165201 22693356 22084396 26725216 22952903


    Sources:
    JAX-CKB

  • BEVACIZUMAB   KRAS

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Sorafenib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    23828442 21216929 28632865 25363205


    Sources:
    JAX-CKB CIViC

  • OXALIPLATIN   KRAS

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Oxaliplatin + ABT-737
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive

    PMIDs:
    23209813 26540314 26341920 21468686 20921465


    Sources:
    JAX-CKB CIViC

  • DECITABINE   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25968887


    Sources:
    CIViC

  • NILOTINIB   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Nilotinib + SCH772984
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • PEMBROLIZUMAB   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    28039262 28451792


    Sources:
    JAX-CKB CIViC

  • TASELISIB   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type no benefit
    Indication/Tumor Type colorectal cancer
    Evidence Type Actionable

    PMIDs:
    28331003


    Sources:
    JAX-CKB

  • VENETOCLAX   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Venetoclax + VX-11e
    Indication/Tumor Type colorectal cancer
    Response Type no benefit

    PMIDs:
    27974663


    Sources:
    JAX-CKB

  • EVEROLIMUS   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant

    PMIDs:
    23629727 22662154 26725216 20664172 20664174


    Sources:
    ClearityFoundationBiomarkers JAX-CKB

  • PF-04691502   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    26725216 21750219


    Sources:
    JAX-CKB

  • DS-7423   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type ovarian clear cell adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    24504419


    Sources:
    JAX-CKB

  • DABRAFENIB   KRAS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Dabrafenib + Trametinib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    27312529


    Sources:
    JAX-CKB PharmGKB

  • BMS-754807   KRAS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy BMS-754807 + SCH772984
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • ALPELISIB   KRAS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy ABT-263 + Alpelisib + CGM097 + Trametinib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    27659046 27602501 24608574 27312529


    Sources:
    JAX-CKB

  • PILARALISIB   KRAS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy XL147 + Carboplatin
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    21216929 25637314


    Sources:
    JAX-CKB

  • SAPANISERTIB   KRAS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Indication/Tumor Type lung cancer
    Response Type sensitive

    PMIDs:
    26574479 26272063


    Sources:
    JAX-CKB

  • CABOZANTINIB   KRAS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type thyroid medullary carcinoma
    Response Type sensitive
    Approval Status Phase III

    PMIDs:
    27525386


    Sources:
    JAX-CKB

  • TRASTUZUMAB   KRAS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Neratinib + Trastuzumab
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    27108243 26243863


    Sources:
    JAX-CKB

  • APITOLISIB   KRAS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colon cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    25673820 21998291


    Sources:
    JAX-CKB

  • LENALIDOMIDE   KRAS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + lenalidomide
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive

    PMIDs:
    27458141


    Sources:
    JAX-CKB

  • ADAVOSERTIB   KRAS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MK-1775 + Cisplatin
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive

    PMIDs:
    27998224 24791855 28652249


    Sources:
    JAX-CKB

  • SONOLISIB   KRAS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    18493606


    Sources:
    JAX-CKB

  • NIVOLUMAB   KRAS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28525386


    Sources:
    CIViC

  • GEFITINIB   KRAS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gefitinib + Trametinib
    Indication/Tumor Type lung cancer
    Response Type no benefit

    PMIDs:
    25870145 15696205 27338794 21258250 19794967 23313110


    Sources:
    ClearityFoundationBiomarkers JAX-CKB CIViC

  • METFORMIN   KRAS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    23877793 24077915 32444490


    Sources:
    JAX-CKB CIViC

  • PALBOCICLIB   KRAS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Palbociclib + Trametinib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    26369631 27167191 1291017 26658964


    Sources:
    JAX-CKB CIViC

  • CI-1040   KRAS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    19018267 19372556


    Sources:
    JAX-CKB

  • GEMCITABINE   KRAS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type biliary tract cancer
    combination therapy Panitumumab + Gemcitabine + Oxaliplatin
    Approval Status Phase Ib/II

    PMIDs:
    26540314 27975152 26091808 26156229 27167172 26228206 24915778 21862683


    Sources:
    JAX-CKB CIViC

  • COPANLISIB   KRAS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Copanlisib + Refametinib
    Indication/Tumor Type biliary tract cancer
    Response Type sensitive

    PMIDs:
    24170767


    Sources:
    JAX-CKB

  • DASATINIB   KRAS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Dasatinib + Demcizumab
    Indication/Tumor Type lung adenocarcinoma
    Response Type sensitive

    PMIDs:
    20956938 27222538 26725216 28280091 27231123 26855149


    Sources:
    JAX-CKB CIViC

  • VOXTALISIB   KRAS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type colorectal cancer
    Response Type sensitive
    Approval Status Preclinical - Cell culture

    PMIDs:
    24634413


    Sources:
    JAX-CKB

  • VEMURAFENIB   KRAS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type resistant

    PMIDs:
    27312529


    Sources:
    JAX-CKB PharmGKB

  • CARBOPLATIN   KRAS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy XL147 + Carboplatin
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    26307133 21216929 16043828 27998224 25637314 22139083


    Sources:
    JAX-CKB CIViC

  • SORAFENIB   KRAS

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Sorafenib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    23629727 26743856 23224737 26307133 25294897 27480147 25363205


    Sources:
    JAX-CKB

  • IXABEPILONE   KRAS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ixabepilone + Sunitinib
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive

    PMIDs:
    26864210


    Sources:
    JAX-CKB

  • PONATINIB   KRAS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ponatinib + Trametinib
    Indication/Tumor Type pancreatic cancer
    Response Type sensitive

    PMIDs:
    27338794


    Sources:
    JAX-CKB

  • INFIGRATINIB   KRAS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type sensitive

    PMIDs:
    27338794


    Sources:
    JAX-CKB

  • CAMPTOTHECIN   KRAS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Gedatolisib + Camptothecin
    Indication/Tumor Type colon cancer
    Response Type sensitive

    PMIDs:
    24042735 25688157


    Sources:
    JAX-CKB

  • PANULISIB   KRAS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • MIDOSTAURIN   KRAS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Midostaurin + SCH772984
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type sensitive

    PMIDs:
    26725216


    Sources:
    JAX-CKB

  • DOCETAXEL   KRAS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Selumetinib + Docetaxel
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type no benefit

    PMIDs:
    26125448 27876675 23200175 28492898


    Sources:
    JAX-CKB CIViC

  • SUNITINIB   KRAS

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Phase I
    Response Type predicted – sensitive
    combination therapy Ixabepilone + Sunitinib

    PMIDs:
    26864210 23455880


    Sources:
    JAX-CKB

  • OLAPARIB   KRAS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    28363999


    Sources:
    JAX-CKB

  • LAPATINIB   KRAS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trastuzumab + Lapatinib
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    27108243


    Sources:
    JAX-CKB

  • LEUCOVORIN   KRAS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20921465


    Sources:
    CIViC

  • FASUDIL   KRAS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy bortezomib + fasudil
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type sensitive

    PMIDs:
    22541434


    Sources:
    JAX-CKB

  • PACLITAXEL   KRAS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type resistant
    combination therapy Carboplatin + Erlotinib + Paclitaxel
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    26307133 21216929 16043828 22139083


    Sources:
    JAX-CKB CIViC

  • SIROLIMUS   KRAS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type pancreatic ductal adenocarcinoma
    Response Type conflicting
    Approval Status Preclinical

    PMIDs:
    26882569 26144316


    Sources:
    JAX-CKB

  • ROMIDEPSIN   KRAS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • PAZOPANIB   KRAS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type thyroid cancer
    Response Type sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    26324075


    Sources:
    JAX-CKB

  • FLUOROURACIL   KRAS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan
    Indication/Tumor Type colorectal cancer
    Response Type no benefit

    PMIDs:
    26341920 20921465


    Sources:
    JAX-CKB CIViC

  • CISPLATIN   KRAS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MK-1775 + Cisplatin
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive

    PMIDs:
    25081901 27040853 28652249


    Sources:
    JAX-CKB CIViC

  • CAPECITABINE   KRAS

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Bevacizumab + Capecitabine
    Indication/Tumor Type colorectal cancer
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • BORTEZOMIB   KRAS

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical
    Response Type sensitive

    PMIDs:
    22541434


    Sources:
    JAX-CKB

  • VANDETANIB   KRAS

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • Ensembl: ENSG00000133703

    • Version: 101_38

    Alternate Names:
    KRAS Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • CancerCommons: KRAS

    • Version: 25-July-2013

    Alternate Names:
    3485 Entrez Gene ID

    Gene Info:
    CancerCommons Reported Gene Name KRAS-RAS

    Publications:

  • TdgClinicalTrial: P01116

    • Version: January-2014

    Alternate Names:
    KRAS Gene Symbol

    Gene Info:
    Target Class Miscellaneous
    Target Subclass Miscellaneous
    Target Subclass Hras

    Publications:

  • JAX-CKB: KRAS

    • Version: 27-September-2017

    Alternate Names:
    3845 CKB Entrez Id
    KRAS CKB Gene Synonym
    C-K-RAS CKB Gene Synonym

    Gene Info:

    Publications:
    Hong et al., 2016, Targeting the PI3K signaling pathway in KRAS mutant colon cancer., Cancer Med
    Park et al., 2012, NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations., Int. J. Oncol.
    Vansteenkiste et al., 2015, Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study., J Thorac Oncol

  • PharmGKB: KRAS

    • Version: 18-August-2020

    Alternate Names:
    PA30196 PharmGKB ID

    Gene Info:

    Publications:
    Rowland et al., 2016, Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours., Eur. J. Cancer
    Gajate P et al., 2012, Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab., Clin Colorectal Cancer
    Sclafani F et al., 2015, Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial., Ann Oncol

  • CIViC: KRAS

    • Version: 14-September-2020

    Alternate Names:
    3845 Entrez Gene ID
    30 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE, CLINICALLY ACTIONABLE

    Publications:
    Patricelli et al., 2016, Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State., Cancer Discov
    Azuara et al., 2016, Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies., Mol. Cancer Ther.
    De Roock et al., 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis., Lancet Oncol.

  • DoCM: KRAS

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Rowland et al., 2016, Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours., Eur. J. Cancer
    Tyner et al., 2009, High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients., Blood
    Kloos et al., 2009, Phase II trial of sorafenib in metastatic thyroid cancer., J. Clin. Oncol.

  • TALC: K-RAS

    • Version: 12-May-2016

    Alternate Names:
    K-RAS Gene Symbol

    Gene Info:

    Publications:

  • OncoKB: KRAS

    • Version: 23-July-2020

    Alternate Names:
    RASK2 OncoKB Gene Synonym
    3845 OncoKB Entrez Id
    KI-RAS OncoKB Gene Synonym

    Gene Info:

    Publications:

  • Tempus: KRAS

    • Version: 11-November-2018

    Alternate Names:
    KRAS Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • TTD: GTPase KRas

    • Version: 2020.06.01

    Alternate Names:
    KRAS TTD Gene Abbreviation
    T48598 TTD Target ID

    Gene Info:

    Publications:

  • MskImpact: KRAS

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • MyCancerGenomeClinicalTrial: KRAS

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationBiomarkers: KRAS

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • FoundationOneGenes: KRAS

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: KRAS

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Oncomine: KRAS

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21